Clinical Trial Update: Ibrutinib and Acalabrutinib Use and Risk of Atrial Fibrillation in Patients With Chronic B-cell Malignancies

View source ↗

Summary

This clinical trial update discusses the use of BTK inhibitors ibrutinib and acalabrutinib and the associated risk of atrial fibrillation in patients with chron…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Malignancies

Drugs mentioned

• CALQUENCE (ACALABRUTINIB)
• IMBRUVICA (IBRUTINIB)

Snippet

Sponsor: University Hospital, Caen | Conditions: Chronic B-cell Malignancies, BTK Inhibitors | Status: ACTIVE_NOT_RECRUITING